Treatment for sickle cell disease in Africa: Should we invest in haematopoietic stem cell transplantation?

Pan African Medical Journal

Volumn 18, Issue , 2014, Pages

  Pule, Gift ^a   Wonkam, Ambroise ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Africa; Haematopoietic stem cells transplantation; Hydroxyurea; Sickle cell disease

Indexed keywords

HYDROXYUREA;

AFRICA; BLOOD TRANSFUSION; DIET THERAPY; DRUG EFFICACY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; MORBIDITY; MORTALITY; NOTE; SICKLE CELL ANEMIA; SURVIVAL RATE; THERAPY EFFECT; ANEMIA, SICKLE CELL; COST OF ILLNESS; PROCEDURES;

AFRICA; ANEMIA, SICKLE CELL; COST OF ILLNESS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS;

EID: 84901236388     PISSN: 19378688     EISSN: None     Source Type: Journal    
DOI: 10.11604/pamj.2014.18.46.3923     Document Type: Note

References (46)

1. Bartolucci P and Galacteros F. Clinical management of adult sickle-cell disease. Curr Opin Hematol. 2012; 19(3):149-155.
2. Flint J, Harding RM, Boyce AJ, Clegg JB. The population genetics of the haemoglobinopathies. Baillieres Clin Haematol. 1998; 11(1):1-51.
3. Nagel RL, Fabry ME, Pagnier J, Zohoun I et al. Hematologically and genetically distinct forms of sickle cell anaemia in Africa-The Senegal type and the Benin type. N Engl J Med. 1985; 312(14):880-884.
4. Piel FB, Patil AP, Howes RE, Nyangiri OA et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013; 381(9861):142-151.
5. Rahimy MC, Gangbo A, Ahouignan G and Alihonou E. New born screening for sickle cell disease in the Republic of Benin. J Clin Pathol. 2009; 62(1):46-48.
6. Wonkam A, De Vries J, Royal C et al. Would you terminate a pregnancy affected by Sickle Cell Disease? Analysis of views of patients in Cameroon. J Med Ethics. 2013; 0:1-6 doi: 10.1136/medethics-2013-101392.
7. Ruffieux N, Njamnshi AK, Wonkam A, Hauert CA et al. Association between biological markers of sickle cell disease and cognitive functioning amongst Cameroonian children. Child Psychol. 2013; 19(2):143-160.
8. Moskowitz JT, Butensky E, Harmatz P, Vichinsky E et al. Caregiving time Sickle Cell Disease: Psychological effects in maternal caregivers. Pediatr Blood Cancer. 2007; 48(1):64-71.
9. Brandow AM, Brousseau DC and Panepinto A. Postdischarge pain, functional limitations and impact on caregivers of children with sickle cell disease treated for painful events. Brit J Haematol. 2009; 144(5):782-788.
10. Makani J, Ofori-Acquah SF, Nnodu O, Wonkam A et al. Sickle Cell Disease: New Opportunities and Challenges in Africa. Scientific World Journal. 2013; Article ID 193252: 16 pages.
11. Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood. 2004; 103(11):4023-4027.
12. Grosse SD, Odame I, Atrash HK, Amendah DD, et al. Sickle Cell Disease in Africa: A neglected cause of early childhood mortality. Am J Prev Med. 2011; 41(6):398-405.
13. Ballas SK, Kesen MR, Goldberg MF, Lutty GA et al. Beyond the definitions of the phenotypic complications of Sickle Cell Disease: an update on management. Scientific World Journal. 2012; 2012:949535.
14. Ware RE and Helms RW. Stroke with transfusion changing to hydroxyurea (SWiTCH): a phase 3 randomized clinical trial for treatment of children with sickle cell anemia, previous stroke, and iron overload. Blood. 2012; 119(17):3925-3932.
15. Atz AM, Wessel DL. Inhaled nitric oxide in sickle cell disease with acute chest syndrome. Anesthesiology. 1997; 87(4):988-990.
16. Alhashimi D, Fedorowicz Z, Alhashimi F, Dastgiri S. Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database Syst Rev. 2010; (1):CD007843.
17. Osaro E and Charles AT. The challenges of meeting the blood transfusion requirements in Sub-Saharan Africa: the need for the development of alternatives to allogenic blood. J Blood Med. 2011; 2:7-21.
18. Bugge HF, Karlsen NC, Oydna E, Rake MM et al. A study of blood transfusion services at a district hospital in Malawi. Vox Sang. 2013; 104(1):37-45.
19. Vichinsky EP. Current issues with blood transfusions in sickle cell disease. SeminHematol. 2001; 38(1):14-22.
20. Petz LD, Calhoun L, Shulman IA, Johnson C et al. The sickle cell hemolytic transfusion reaction syndrome. Transfusion. 1997; 37(4):382-92.
21. Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol. 2001; 38(1):30-6.
22. Platt OS, Orkin SH, Dover G, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest. 1984; 74(2):652-6.
23. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of Hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010; 115(12):2354-2363.
24. Zimmerman SA, Schultz WH, Burgett S, Mortier NA et al. Hydroxyurea therapy lowers transcranialdoppler flow velocities in children with sickle cell Anaemia. Blood. 2007; 110(3):1043-1047.
25. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial PediatricHydroxyurea Group. Blood. 1999; 94(5):1550-1504.
26. Thornburg CD, Dixon N, Burgett S, et al. A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. Pediatr Blood Cancer. 2009; 52(5):609-615.
27. Alvarez O, Miller ST, Wang WC. Effect of Hydroxyurea Treatment on Renal Function Parameters: Results from the Multi-Center Placebo-Controlled BABY HUG Clinical Trial for Infants with Sickle Cell Anemia. Pediatr Blood Cancer. 2012; 59(4):668-674.
28. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995; 332(20):1317-1322.
29. Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med. 2008; 148(12):932-938.
30. Bethesda MD. National Institutes of Health. The Management of Sickle Cell Disease. 2002; 161-165.
31. Lanzkron S, Strouse JJ, Wilson R, et al. Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med. 2008; 148(12):939-955.
32. Brandow AM, Jirovec DL, Panepinto JA. Hydroxyurea in children with sickle cell disease: Practice patterns and barriers to utilization. Am J Hematol. 2010; 85(8):611-613.
33. Zumberg MS, Reddy S, Boyette RL, et al. Hydroxyurea therapy for sickle cell disease in community-based practices: A survey of Florida and North Carolina hematologists/oncologists. Am J Hematol. 2005; 79(2):107-113.
34. Thornburg CD, Calatroni A, Telen M, et al. Adherence to hydroxyurea therapy in children with sickle cell anemia. J Pediatr. 2010; 156(3):415-419.
35. Bethesda MD. National Heart, Lung, and Blood Institute (NHLBI). Hydroxyurea to prevent organ damage in children with sickle cell anemia. Clin Trials. 2010.
36. Mulaku N, Opiyo N, Karumbi J, Kitonyi G. Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries. Arch Dis Child. 2013; 98(11):908-914.
37. Kenyan Ministry of Health. Clinical guidelines for management and referral of common conditions at levels 4-6. Hospitals. 2009; 3:259-261.
38. Bernaudin F, Socie G, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood. 2007; 110(7):2749-2756.
39. Johnson FL, Look AT, Gockerman J, Ruggiero MR et al. Bone-marrow transplantation in a patient with sickle-cell Anaemia. N Engl J Med. 1984; 311(12):780-783.
40. Milpied NHJ, Garand R, David A. Bone marrow transplantation for sickle cell anaemia (letter). Lancet. 1988; 2(8606):328-329.
41. Oringanje C, Nemecek E, Oniyangi O. Hematopoietic stem cell transplantation for people with sickle cell disease. Cochrane Database Syst Rev 2013; 5:CD007001.
42. Artkins RC, Walter MC. Hematopoietic cell transplantation in the treatment of sickle cell disease. Exp Opin Biol Therapy. 2003; 3(1):1-10.
43. Gratwohl A, Baldomero H, Gratwohl M, Aljurf M et al. Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica. 2013; 98(8):1282-1290.
44. Mahmoud HK, El-Haddad AM, Fahmy OA, El-Emary M et al. Hematopoietic stem cell transplantation in Egypt. Bone Marrow Transplant. 2008; 42(1):76-80.
45. Modell B, Darlison M. Global epidemiology of hemoglobin disorders and derived service indicators. Bull World Health Organ. 2008; 86(6):480-487.
46. Wheatherall DJ. Hemoglobinopathies worldwide: present and future. Curr Mol Med. 2008; 8(7):592-599.